Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. SPY
4. DFTX
5. AZN
6. SATL
7. SRRK
8. LYNX
9. BBNX
10. USO

Go back to Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
(NASDAQ: ROIV) Delayed: 40.89 +0.07 (0.17%)
Previous Close $40.82    52 Week High $ 
Open $40.64    52 Week Low $ 
Day High $41.33    P/E N/A 
Day Low $40.44    EPS $ 
Volume 508,740